CAMBRIDGE, Mass., Dec. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported ...

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis Claudin 18.2 is emerging as a target of clinical ...

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was publi ...

Lynk Pharmaceuticals Co., Ltd. ('Lynk Pharmaceuticals'), a clinical-stage innovative drug development company focused on ...

As increasing trial complexity becomes a regulatory risk, sponsor expectations of CROs and data partners are changing.

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation One hundred and seven ...

Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based (RSVpreF) vaccine in this ...

Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024 CORAL GABLES, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc.

In the 21st century, artificial intelligence (AI) has emerged as a valuable approach in data science and a growing influence in medical research, 4-6 with an accelerating pace of innovation. This ...